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Atrial natriuretic factor determinations and chronic sodium
homeostasis. To examine the physiological role of atrial natriurctic
factor (ANF) in the maintenance of sodium homeostasis under various
conditions, we performed experiments in rats across a wide range of
sodium intake, in rats with chronic renal insufficiency at extremes of
sodium intake, and in rats given desoxycorticosterone acetate. After
three weeks of a very low sodium diet, regular diet, or regular diet plus
1% saline as drinking water, no difference in plasma values of im-
munoreactive atrial natriuretic factor (IR-ANF) were identified, while
rats at the lowest level of sodium intake had elevated atrial values.
Normal rats, and rats with 5/6 nephrectomy had plasma values of
IR-ANF which were no different irrespective of their sodium intake,
nor were atrial values in these rats different. Although mineralocor-
ticoid "escape" could be documented by changes in urine sodium
excretion, neither plasma nor atrial IR-ANF values showed differences
either at 24 or 72 hr after "escape". The data are consistent with
previous observations that ANF serves the purpose of affecting rapid
adjustments to large alterations in circulating fluid volume. Chronic
high sodium intake, adaptation to renal insufficiency, and adjustment to
the effect of mineralocorticoid do not appear to be associated with
increased circulating plasma concentrations of IR-ANF.
Atrial natriuretic factor (ANF), which is released from
membrane—bound storage granules within atrial muscle cells
u—sI, is a peptide(s) which promotes vasodilatation, natriure-
sis, kaliuresis, and diuresis [6]. ANF has recently been charac-
terized [7], the sequences of a variety of atrial peptides are
known [8—15], and radioimmunoassays to ANFs in both atrial
tissue and plasma have been described [16—19]. The mechanism
of action and the potential significance of ANF has been the
topic of recent scholarly reviews [20, 21]. The implications of
natriuretic materials to the understanding of basic renal physi-
ology are considerable. The development of a radioimmunoas-
say to ANF in our laboratory [22, 231 provided us the opportu-
nity to examine the role of this material in the regulation of fluid
volume. We addressed the following questions by measuring
ANF (JR-ANF) in plasma and atrial tissue: does ANF play a
role in the adaptation to very high sodium intake; is ANF
important in sodium regulation in renal insufficiency; and is the
"escape" from mineralocorticoid effects mediated by ANF. We
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sought to gain insight into these questions by examining rela-
tionships between plasma and atrial IR-ANF values and
changes in sodium homeostasis and/or renal function. We were
unable to attribute long—term sodium homeostasis, the renal
adaptation to decreases in total nephron mass, or the "escape"
from mineralocorticoid effects to appreciable increases in cir-
culating concentration of IR-ANF.
Methods
Male Wistar rats weighing 250 to 275 g were used for the
studies. Animals were housed in plastic cages or singly in
metabolism cages as indicated, and were maintained in a facility
designed to control temperature constant at 21°C, relative
humidity 50%, and a dark—light periodicity of 12:12 hr. Prior to
the protocols to be described, standard food (Altromin, sodium
2.2 g/kg) and tap water were allowed ad libitum.
Dietary sodium intake
Thirty rats were randomly assigned to one of three groups
ingesting one of three dietary sodium intakes: low sodium food
(Altromin, sodium 150 mg/kg), regular diet (vide supra), or
regular food coupled with 0.9% sodium chloride solution as
drinking water. These dietary intakes were continued for 21
days. Thereafter, the animals were singly housed in metabolism
cages and urine was collected for 24 hr. Urinary sodium and
aldosterone excretion were determined in these specimens. On
the morning following the urine collections, the animals were
gently anesthetized with pentobarbital (Nembutal, Eli Lilly,
Indianapolis, Indiana, USA) and were then decapitated with a
guillotine. Blood was collected for renin and IR-ANF determi-
nations. The hearts were rapidly excised, and the tissue snap
frozen in liquid nitrogen. Renin in plasma and aldosterone in
urine were determined by radioimmunoassay as described
elsewhere [24, 25]. Sodium was measured by flame photometry.
In addition, a brief dietary protocol was conducted with 24 rats
which were first given the low sodium food for one week.
Thereafter, 16 animals were given the high sodium regimen.
Eight animals were sacrificed after 24 hr of the regimen as
described above. The additional eight high sodium intake
animals, as well as the eight low sodium intake control animals,
were sacrificed after 72 hr of the high sodium intake.
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Chronic rena/failure experiments
The induction of chronic renal failure was affected by means
of two—stage 5/6 nephrectomy described in detail elsewhere
[261. Briefly, the rats were anesthetized with ether. The left
kidney was exposed via a flank incision. The adrenal gland was
identified so as not to be injured. The upper and lower pole of
the kidney were removed with a razor blade to leave only a hilar
remnant. Hemostasis was maintained with gentle pressure. One
week later, the animals were again anesthetized and the right
kidney was completely removed via another flank incision.
Care was taken to maintain integrity of the right adrenal gland.
Control animals underwent identical preparation, anesthesia,
and incision; however, their renal tissue was manipulated
without being removed.
Control and 5/6 nephrectomy animals were randomly as-
signed to either a regimen of distilled water and low sodium
food, or regular food and 0.9% drinking water. After three
weeks, the animals were lightly anesthetized with ether, and
blood was taken from the inner canthus of the eye for determi-
nation of plasma ANF values. Thereafter, the animals were
singly housed in metabolism cages and their urine was collected
for 24 hr to estimate their dietary sodium intake.
Rats were studied following the 24 hr urine collections. On
the day prior to the clearance studies, each rat was lightly
anesthetized with methylhexital (Brevimetal, Eli Lilly, Inc.)
and a polypropylene catheter was placed into a femoral artery
(PP 10), and vein (PP 25). On the morning of the study, each rat
was anesthetized with mactin (Byk Gulden, Konstanz, FRG)
0.01 g, 100 g body wt) and placed on a controllable heating pad.
After tracheostomy, the bladder was cannulated with PP 90
polypropylene tubing. Bladder dead space was held to a mini-
mum by advancing the catheter tip close to the trigone where it
was tied into place. Fluid losses were replaced by I mliter of
0.15454 NaCl solution which contained the priming doses of 20
uCi (3H)-methoxyinulin (New England Nuclear, Boston, Mas-
sachusetts, USA). Loading doses were followed by mainte-
nance infusion at 1% of body wt per hr of 0.154 M NaC1,
containing 13 mCi of (3H)-inulin. After 1 hr for equilibration,
four clearance measurements of 20 mm each were conducted; a
300 diter arterial blood sample was obtained at the midpoint of
each. Urine was collected in pre-weighed tubes and direct mean
arterial pressure (MAP) recorded continuously (Gould Inc.,
Cleveland, Ohio, USA). The hematocrit was determined in a
microhematocrit centrifuge (Model 1 MB, Damon IEC Div.,
Needham Heights, Massachusetts, USA) and the plasma sepa-
rated. Samples of urine and plasma were stored at —20°C. The
glomerular filtration rate (GFR) was accepted as the clearance
of inulin.
Urine and plasma concentrations of inulin were determined
by measuring the radioactivity of (3H) using liquid scintillation
techniques [27]. The sodium concentration was determined by
flame photometry. Clearance was calculated as described pre-
viously [27]. Parts of the clearance analysis and all of the
sodium determinations were performed by laboratory personnel
not aware of the experimental information on the animals under
study. Following the last urine collection, 2 mliter of whole
blood were gently aspirated from the arterial catheter for the
determination of ANF, and the animals were sacrificed. From
some animals, the hearts were immediately excised at the
termination of the studies, and the atria were snap frozen with
liquid nitrogen for subsequent ANF assay.
DOCA escape experiments
To evaluate a potential role of ANF in the escape from
mineralocorticoid effects, we employed the model previously
described by Moehring and Moehring [28]. Briefly, 24 animals
were housed in metabolism cages and allowed five days to
familiarize themselves with their surroundings. The animals
were given 20 g regular food as powder mixed in 20 mliter
distilled water daily. Measured amounts of drinking water were
offered. Urine was collected in two 12 hr aliquots daily for
sodium and potassium determinations. After five balance days,
DOCA in oil (Percorten, Ciba Geigy, Summit, New Jersey,
USA) 5 mg/kg was given subcutaneously at 0800 and 2000 hr for
three days. Eight animals were sacrificed at 24 hr at which time
sodium retention and subsequent escape had been documented.
Eight oil—vehicle injected rats, and the additional DOCA in-
jected animals were sacrificed at 72 hr. The animals were
anesthetized with pentobarbital, and were decapitated, Blood
and atrial tissue were obtained as outlined above.
Dose—response relationships
To establish the response to synthetic ANF in our animal
model, we anesthetized rats and placed catheters into the
femoral artery and vein. These animals were subsequently
anesthetized with mactin, their tracheae and bladders can-
nulated as described, and the above loading and maintenance
infusion of saline solution given. Urine was collected for one hr
as described, and blood pressure was continuously monitored.
Synthetic ANF (atriopeptin III, Bachem GmbH, Basel, Swit-
zerland), as first described by Currie et al [9], was given
incrementally in doses of 25, 50, 100, 250, 500, and 1000 ng
bolus injections. Urine was collected in 10 mm aliquots before
and after each dose of atriopeptin III. A minimum of 30 mm
between doses was allowed for recovery. Urinary losses were
repleted by intravenous infusion. Blood pressure was moni-
tored and recorded continuously.
IR-ANF assay in plasma and atrial tissue
Details of the assay procedures are published elsewhere [22].
Blood was collected in tubes containing aprotinin, soybean
trypsin inhibitor, and EDTA. Plasma was separated by centri-
fugation and processed for extraction of ANF immunoreactivity
as follows: two mliter of each sample were diluted with three
volumes of 4% acetic acid and after centrifugation pumped at a
rate of 4 mliter/min through a small column containing octa-
decasilyl-silica particles (ODS Porasil, Machrey and Nagel,
FRG). After a wash with 5 mliter water, the absorbed peptides
were eluted with a solution of 86% methanol in 4% acetic acid.
After evaporation and lyophilization, the dry residue was
dissolved in radioimmunoassay buffer for determination of
mR-AN F. Antibody was obtained from rabbits immunized with
synthetic atriopeptin II (Bachem) [91. Synthetic atriopeptin III
at a concentration from 1.95 to 1000 pg/tube was used for the
construction of standard curves. The incubation mixture con-
sisted of 0.2 mliter buffer, 0.1 mliter antibody (final dilution
1:80,000). Tracer (4,000 cpm/tube) was added after 48 hr at 4°C.
After an overnight second incubation, separation of free from
antibody—bound 125 1-peptide was achieved by the addition of
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0.2 muter dextran coated charcoal. Using this procedure, the
lowest concentration of atriopeptin III that yielded a binding
which differed significantly from binding in the absence of
standard at the 95% confidence interval was 2 pg/tube. The 50%
intercept was at 41 pg/tube. The inter-assay variation was 7.1%
(N = 10). Rat atrial tissue was minced and boiled for 15 mm in
0.1 M HCI to avoid proteolysis. The cooled tissue was subse-
quently homogenized and centrifuged for 30 mm at 3000 X g.
The resulting supernatant was extracted using ODS-silica car-
tridges as described for plasma. For studies on the recovery of
ANF from plasma, various dilutions of synthetic AP III were
added to plasma treated with charcoal for elimination of endog-
enous peptides. Using the ODS cartridges procedure for extrac-
tion, the recovery of synthetic AP III ranged from 62 to 70% (N
= 10) both in the upper and lower ranges of the standard curve.
The serial dilutions of extracts from rat plasma as well as atrial
tissue inhibited the binding of tracer to antibody in parallel with
the standard curve of AP III.
Statistical analysis
The data were examined by means of two—way analysis of
variance, linear regression analysis, and Student's t-test as
appropriate. Power calculations were performed with assump-
tions of unpaired 1-tests with a significance level of 0.05. The
ninety—five per cent limits of probability were accepted as
significant. Fiducial limits are expressed as standard deviation.
Results
ANF and sodium intake
The upper panel of Figure 1 contains the 24 hr urinary sodium
excretion data of rats subjected to three weeks of uniform
sodium intake across a wide range of intakes. The range of
excretion extended from 2.9 2.2 to 1083 97 uEq/100 g/24
hr. The middle panel shows the effects of the regimens on
plasma renin activity and urinary aldosterone excretion. So-
dium loading resulted in a significant suppression of this hu-
moral regulatory system. The effect of the intervention on
IR-ANF in plasma and atrial tissue is shown in the lower panel
of Figure 1. No significant influence on plasma concentrations
of IR-ANF could be shown; however, IR-ANF concentration in
atria after three weeks of low sodium intake was significantly
higher than either following the ingestion of regular food, or the
high sodium regimen for the same period. On the other hand, no
significant influence on either plasma or atrial values could be
demonstrated after one or three days of the high sodium
regimen compared to the low sodium regimen. The plasma
values were: low sodium, 30.5 7.1, high sodium day 1, 26.7
7, high sodium day 3, 22.8 12 pg/mliter respectively. The
corresponding atrial values were: 349 156, 265 104 and 275
127 ng/mg protein respectively (P = NS).
ANF in chronic renal insufficiency
In Figure 2, upper panel are shown the 24 hr urinary sodium
excretion of either normal or chronic renal failure rats ingesting
either low or high sodium intake, as well as the inulin clearance
values obtained on the following day (middle panel). The
sodium excretion was commensurate with intake in the four
groups. Inulin clearance was significantly different in all groups
(P < 0.05). Normal rats ingesting high sodium food had higher
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Fig. 1. Rats at three levels of sodium intake exhibited the expected
significant increments in sodium excretion, and decrements in renin
(hatched bars) and aldosterone (open bars). Plasma IR-ANF values (0)
were not different among the regimens. Atrial IR-ANF (0) was greater
at low sodium intake compared to either normal or high sodium intake.
*different from previous value (P < 0.05).
values than normal rats receiving a low sodium intake. Simi-
larly, rats with reduced renal mass exhibited a greater glomer-
ular filtration rate when receiving high sodium intake compared
to low sodium intake. However, plasma IR-ANF values (lower
panel), either obtained from the ocular venous plexus on the
day prior to the clearance values (first bar), or those obtained at
the termination of the clearance experiments (second bar) were
not influenced by renal function or sodium intake and thus were
not different (P = NS). Atrial tissue for IR-ANF was obtained
at the high level of sodium intake in chronic renal failure and
control animals. These values (244 126 and 277 121 nglmg
protein) were not different (P = NS).
ANF in DOCA escape
The upper panels of Figure 3 show urinary sodium excretion
at night (upper) and during the day (lower) for 72 hr prior to, and
36 hr after injection of DOCA in 16 rats, (hatched and stippled
bars) or its vehicle in control rats (open bars). Sodium retention
following DOCA was documented in the first 12 hr period after
its administration (P <0.05). Thereafter, urinary sodium excre-
tion was no different among the groups. Eight DOCA rats were
sacrificed at 24 hr (hatched bars) after receiving the drug, while
eight additional rats (stippled bars), and the eight control rats
were sacrificed at 72 hr. In the lower panel (Fig. 3) are the
IR-ANF values in either plasma (first bar) or atrial tissue
(second bar) of the DOCA and control rats. No significant
differences could be identified.
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Fig. 2. Rats with 5/6 nephrectomy (CRF) at low and high sodium intake,
and normal rats at the same intakes had incrementally different
filtration rates. Plasma IR-ANF values either before or following the
clearance determinations were not different. *different from previous
value (P < 0.05).
Dose—response relationship
MAP and UNaV, as determined before and after each incre-
mental dose of atriopeptin III, were evaluated with analysis of
variance. No significant influence on these variables could be
identified through time (P = NS), suggesting that adequate
recovery occurred between doses of atriopeptin III. Conse-
quently, since the pre-atriopeptin III values were not different,
only the first pre-dose value of MAP and UNaV is shown in
Figure 4. After injection of atriopeptin III MAP fell abruptly
with 20 sec, and proceeded to recover in the subsequent 3 to 6
mm. The post dose values in Figure 4 are the lowest levels
achieved. A significant influence of ANF on blood pressure was
identified at the 25 ng dose, while UNaV, obtained for 10 mm
after each dose, was not significantly altered until the 100 ng
dose (P < 0.05). Regression analyses performed on the results
obtained from each rat were pooled and demonstrated the
following relationships: MAP = 153.1 — 25.6 (log dose
atriopeptin III) (r = 0.70, P < 0.001); UNaV = —4.51 +4.78
(log dose atriopeptin III) (r = 0.84, P < 0.001).
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Fig. 3. With the administration of DOCA, transient sodium retention
occurred. Plasma and atrial ANF values at 24 or 72 hours were not
influenced.
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Fig. 4. Dose response to atriopeptin III caused sign{ficant, transient
decreases in blood pressure at a 25 ng or greater bolus injection.
Significant natriuresis occurred at the 100 ng injection and thereafter.
*p < 0.05.
Discussion
In our previous studies we examined the effect of acute and
large scale volume expansipn on plasma concentrations of ANF
[22]. We found that by inducing an increase in circulating fluid
volume of 2 mliter in 250 g rats we could significantly increase
plasma ANF concentrations, and that with 8 mliter whole blood
or saline, plasma values were increased tenfold. Experiments
with a Langendorf isolated heart preparation [22, 23] indicated
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that an increase in atrial wall tension was associated with
release of ANF in a system independent of nerve supply or
humoral influences, These studies, which corroborated the
findings of Dietz [29], indicated an important role for ANF in
the adjustment to acute changes in fluid volume. Further, the
earlier studies [22] also suggested that the half—life of released
ANF was short.
To examine a potential role for ANF to adjustments in oral
salt intake over a wide range, we studied extremes of sodium
intake over a period of three weeks. The range of sodium
excretion in our rats exceeded a thousandfold. Whereas the
expected adjustments in renin and aldosterone were clearly
operative, we found no influence on plasma values of IR-ANF.
However, atrial concentrations of rats ingesting a very low
sodium intake were greater than those of rats receiving regular
food or rats which received a large sodium intake. Elevated
atrial IR-ANF concentrations of rats receiving low sodium
intake correspond to the increased granularity in the atria of
such animals as observed by de Bold [4]. In addition, Schwartz,
Currie and Needleman noted that cardiac levels of IR-ANF, in
either normotensive or hypertensive DahI rats, were inversely
proportional to dietary salt intake [30]. Their results are con-
sistent with our findings in atrial tissue. However, our results,
and those of Schwartz, Currie and Needleman [30] conflict with
those reported by Tanaka and associates [19], who observed
both an increase in atrial and plasma values of IR-ANF by
adding saline to the drinking water of rats. Similar changes were
reported by Gutkowska et al [31], who also noted reduced atrial
IR-ANF in water—deprived rats while atrial IR-ANF was un-
changed after five days of a sodium deficient diet. We repeated
our studies to include observations after 24 and 72 hr of a high
sodium intake, and could find no influence on either plasma or
atrial IR-ANF values. Our power calculations indicate that we
would have been able to detect a 40 to 50% increase in either
plasma or atrial values. Changes of such magnitude were
reported by Tanaka, Misono and Inagami [19]. The reasons for
the discrepant results observed by ourselves and Tanaka et al
[191 are not clear. Differences in radioimmunoassay technique,
differences in rat species, and differences in protocol are all
possibilities. Our antibody was raised to atriopeptin II. In
addition, we eluted plasma samples with 86% ethanol in 4%
acetic acid. Tanaka et al 119] employed a different ANF antigen,
and their extraction procedure differed in some details from
ours. Their protocol relied on two weeks dietary intervention.
Urine sodium excretory data were not given, however, the
range of sodium intake ingested by their animals should have
been similar to the amounts we employed. We can think of no
reason why Sprague—Dawley rats should produce results dif-
ferent from those obtained in Wistar rats, but the issue is not
settled. Our protocol differed substantially from the one em-
ployed by Gutkowska and coworkers [31]. Elevated plasma
levels of ANF have been identified in volume overloaded
children with renal failure prior to their dialysis treatments [32],
and also in certain patients with cardiac disease [331. In these
instances it is likely that the increases in plasma ANF were
associated with increased atrial pressure and were not related to
homeostasis of dietary sodium intake per se.
The adaptation to diminished nephron mass requires a mas
sive increase in individual nephron sodium excretion and whole
kidney fractional sodium excretion if sodium homeostasis is to
be maintained at usual intakes [34]. How this adaptation comes
about is not entirely clear. In our rats with chronic renal
insufficiency, we established a range of fractional sodium ex-
cretion; however, IR-ANF values in plasma under two different
anesthetic conditions as well as values in atrial tissue in sodium
loaded rats, were not related to differences in fractional sodium
excretion. These results do not support the notion that this
natriuretic hormone plays a major role in the adaptation of
remaining nephrons to a high sodium intake, at least in the
range of renal function studied. However, we cannot exclude
the possibility that glomeruli in the face of reduced number
exhibit an increased individual responsiveness to ANF. A
recent report supports this notion [35].
We conducted additional volume expansion experiments with
DOCA, in an attempt to relate the sodium retention and
subsequent "escape" to changes in ANF. We were able to
detect sodium retention, and the re-establishment of sodium
balance, but were unable to find changes in either atrial or
plasma ANF concentrations at either 24 or 72 hr. Recently,
Ackermann and Irizawa [36] studied volume expansion with
sodium loading combined with DOCA administration. They
found that atrial extracts from rats receiving DOCA and sodium
exerted a greater natriuretic response than did extracts from
control rats. The experiments of Ackerman and Irizawa differed
from our own in that their control rats were sodium deprived
and their DOCA animals also received a 1% saline solution as
drinking water. Ackerman and Irizawa found that fucose, a
glycoprotein precursor, was incorporated more rapidly into the
atria of rats which exhibited extracts with increased natriuretic
activity. This material is incorporated into granule membranes,
and thus is likely associated with granule synthesis. The authors
suggested that ANF plays a role in this model of DOCA-
induced chronic volume expansion, in that granule turnover
appears to be increased and natriuretic activity is enhanced.
Trippodo et al [37] have shown that atrial tissue contains factors
capable of promoting the conversion of ANF from a high to a
low molecular form. Our earlier HPLC studies indicated that
the employed assay for IR-ANF detects series of materials in
atria and plasma which partly overlap [22]. The immunoreactive
materials from atria, for the most part, are of greater molecular
wt than in plasma and may constitute precursors of circulating
ANF.
Recent work from our laboratory revealed that a biologically
active HPLC fraction obtained from isolated heart perfusates
co-elutes with the major immunoreactive fraction we identified
in plasma [23]. This fraction caused rabbit aorta strips to be less
responsive to the vasoconstrictor action of norepinephrine. These
results establish the validity of our IR-ANE assay system. Nev-
ertheless, it is conceivable, that the obtained concentrations of
IR-ANF in plasma and atrial tissue do not fully reflect ongoing
changes in turnover or synthesis of atrial ANF. Further, the short
half—life of ANF in plasma [38] might contribute to the limitations
of interpreting static plasma concentrations.
Our dose—response experiments were performed to elucidate
the relationship between effects on blood pressure and the
genesis of natriuresis. In previous studies of ANF administra-
tion, larger doses of synthetic ANF were given to dogs or rats
than those employed in our studies [49, 50]. We employed bolus
administration in an attempt to separate the dose response
effects on blood pressure from those of natriuresis. We found
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that 25 ng of atriopeptin III significantly lowered blood pres-
sure, and that a correlation between dose of this synthetic ANF
and decrease in blood pressure could be identified. Natriuresis
appeared to require a greater dose. These results support the
notion that ANF may act predominantly via hemodynamic
mechanisms [39—42].
The short half—life of ANF [38], the brief hemodynamic
responses to incremental bolus injections of ANF, the prepon-
derance of hemodynamic to natriuretic responses, and the
release engendered by atrial wall tension [22, 23] support the
notion that this system serves the purpose of affecting rapid
adjustments to large alterations in circulating fluid volume. In
situations involving chronic adjustments to more subtle changes
in sodium intake adjustments in other humoral regulatory
systems, such as the renin—angiotensin—aldosterone axis, may
be sufficient to maintain homeostasis.
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